Nutcracker Therapeutics is an early-stage company that develops and manufactures RNA-based treatments for various diseases. This information is self-described.

Nutcracker Therapeutics

BASE mRNA facility focuses on messenger RNA design, manufacturing, and research. They provide end-to-end research services to design, manufacture, and test new mRNA medicines.

BASE mRNA facility

Nutcracker Therapeutics | 4,043 followers on LinkedIn. Nutcracker Therapeutics is developing mRNA therapeutics and a novel GMP manufacturing platform. | Nutcracker Therapeutics is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA therapeutics platform. Armed with this high-tech advantage, we have developed a wholly owned pipeline of RNA therapeutic programs and established partnership initiatives with top clinical investigators at several leading institutions across the globe. With our platform’s ability to accelerate the development of life-changing RNA therapeutics, we seek to advance breakthrough RNA therapies at high velocity through all stages of development across a variety of indications.

From R to D, too

Babak Sanii

Human Resources Executive | Culture Builder | Leadership Coach

Angela Peters

Carolyn Carrillo

Co-Founder and Chief Executive Officer, Simplify Genomics

Travis Lacey

We're thrilled to be in Boston for this year's PODD conference! Colin McKinlay will be giving a talk on our peptoid-based Nutshell® delivery vehicles.

Our pipeline has gotten a new look! Our therapeutic programs demonstrate the versatility of mRNA as a therapeutic and in vaccines: NTX-250, which targets the HPV infection that causes cervical cancer and dysplasia; NTX-470, which targets metastatic castration-resistant prostate cancer; and NTX-472, which targets B cell autoimmune and lymphoma diseases.

It's been a busy couple of months! Over the past quarter our team presented on the advancement of mRNA therapeutics, our Nutshell® Delivery Vehicles, our Nutcracker® Manufacturing Unit, antigen receptor design for solid tumors, and using machine learning to optimize drug design. Here's to a busy last quarter of the year!

Ray L. will be attending the 16th Drug Discovery Strategic Summit next week in San Francisco. We'd love to see you there!

Gunasekaran (Guna) Kannan shares his thoughts on how mRNA can be used to overcome the development challenges in designing protein therapeutics. Thank you Guna and The Medicine Maker for making this article possible! Read the article here: https://lnkd.in/e4EJdnE9

We'll be at the AI in Drug Discovery Xchange in San Francisco tomorrow! Evan McCartney-Melstad will be leading a roundtable on how machine learning can be used to optimize structure-based drug design.

We're excited that Christian Moreno will be participating in a Cell & Gene panel titled: "From Bottleneck to Breakthrough: Reimagining the mRNA Therapeutics Supply Chain," tomorrow starting at 11AM ET! Tune in here: https://lnkd.in/eRtF-gFF

We'll be at the Antibody Therapeutics Xchange in San Francisco next week on Monday the 23rd! Gunasekaran (Guna) Kannan will be leading a late breaking roundtable discussion on "current challenges in design of bispecific / chimeric antigen receptors for solid tumours," focusing on target identification and specificity, tumor microenvironment barriers, and off-target toxicity and safety concerns. We'd love to see you there!

We'll be at the mRNA Process Development & Manufacturing Summit this week in Boston! Babak Sanii will be giving a talk titled: "Scalable Microfluidic Factories to Manufacture mRNA Personalized Cancer Vaccines." We'd love to see you there!

We can't believe it's September already! Over the last several months, our team members presented on our engineered transmembrane immunomodulator, ENG-LIGHT; our mRNA therapeutic for prostate cancer, NTX-470; our latest therapeutic program for B-cell autoimmune and lymphoma diseases, NTX-472; new methods of delivery for oncology therapeutics; our CodonCracker™ software; and analytical control strategies for the production of quality mRNA.

Metric
Company Name	Nutcracker Therapeutics	BASE mRNA facility
Symbol
MSH ID	COM:NUTCRACKERX	AU:ORG:BASEFACILITY
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	AU
Stage
Employee Count
Website	nutcrackerx.com	basefacility.org.au
LinkedIn	nutcracker-therapeutics	base-facility
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	524
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

NUTC

COM:NUTCRACKERX

Nutcracker Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue